VINCI CAPITAL

Vinci Capital SA is a Swiss venture capital and private equity firm focused on investing in mid and late-stage companies, particularly in the technology and industrial sectors. Established in 2003 and based in Geneva with an additional office in Zug, the firm specializes in various financing strategies, including succession financing, management buy-outs, and corporate spin-offs. Vinci Capital targets small and medium enterprises in Switzerland, typically investing between CHF7 million and CHF10 million in companies with annual sales ranging from CHF20 million to CHF80 million. The firm is particularly interested in sectors such as new media technologies, life sciences, microelectronics, nanotechnology, and software. With over CHF200 million under management, Vinci Capital has a robust track record, having provided equity to over 30 Swiss companies to support innovation and growth. The firm’s investment team brings 40 years of combined experience in private equity, enhancing its capability to navigate complex financial situations.

Xavier Paternot

Managing Director

15 past transactions

beqom

Convertible Note in 2014
Beqom is a cloud-based compensation management software provider, serving leading global enterprises. Its platform, CompComplete, comprises four key components: Pay Management for comprehensive total compensation delivery; Pay Intelligence for data-driven pay optimization; PayAnalytics for closing pay gaps and fostering fairness; and Pay Transparency for employee clarity on compensation and performance. Beqom's technology handles enterprise-scale complexity, enabling companies to meet regulatory requirements, optimize compensation decisions, and enhance business outcomes through unified data and AI-enabled insights.

Anergis

Series A in 2014
Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, specializing in the discovery and development of allergy vaccines. Founded in 2001 by Francois Spertini, Anergis utilizes a proprietary technology known as Contiguous Overlapping Peptides to create vaccines designed for ultra-fast desensitization. The company focuses on developing immunotherapies that target common allergens, including birch pollen, ragweed pollen, and house dust mites. Anergis aims to provide patients with effective, long-term solutions for allergy relief, significantly improving treatment times.

SENSIMED

Series C in 2012
Sensimed AG is a medical devices company based in Lausanne, Switzerland, founded in 2003. The company specializes in the design, development, and commercialization of integrated micro-systems for medical applications, particularly focusing on glaucoma management. Its flagship product, the SENSIMED Triggerfish, is a soft, single-use contact lens that enables continuous monitoring of intraocular pressure (IOP) fluctuations in glaucoma patients over a 24-hour period. The Triggerfish system includes disposable sensors, an adhesive antenna for communication, a battery-powered recorder for data collection, and software for data management and analysis. Sensimed aims to enhance personalized treatment for glaucoma patients by analyzing the collected data to identify pathological patterns and improve clinical outcomes. The company's products are distributed through partners across Europe, Asia-Pacific, the Middle East, and the Americas. As of December 2019, Sensimed operates as a subsidiary of SEED Co., Ltd.

Anergis

Series A in 2011
Anergis is a clinical-stage biopharmaceutical company based in Lausanne, Switzerland, specializing in the discovery and development of allergy vaccines. Founded in 2001 by Francois Spertini, Anergis utilizes a proprietary technology known as Contiguous Overlapping Peptides to create vaccines designed for ultra-fast desensitization. The company focuses on developing immunotherapies that target common allergens, including birch pollen, ragweed pollen, and house dust mites. Anergis aims to provide patients with effective, long-term solutions for allergy relief, significantly improving treatment times.

SolvAxis

Venture Round in 2010
SolvAxis is a leader in the design of ERP systems for SMEs . Since 1987, they offer enterprise software and related services. Their innovative and reliable ProConcept ERP solution lets you create and manage your business processes efficiently. 15'000 users on more than 1000 sites are already working with this standard solution. They are more and more numerous every day. Relationships with their customers, prospects and partners are based on mutual trust. Thus, their employees give your project a great importance. They collaborate with you in a close and constructive way.

Evolva

Post in 2009
Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Evolva

Series B in 2009
Evolva is a biotechnology company based in Reinach, Switzerland, that specializes in the development and commercialization of nature-based ingredients and innovative small-molecule compounds. Founded in 2004, Evolva leverages a proprietary synthetic biology platform to create high-quality ingredients that serve various applications, including flavors, fragrances, health ingredients, and health protection. By mimicking the chemical structures found in natural products, Evolva's technology offers solutions that avoid the limitations associated with traditional methods, thus providing a versatile approach to ingredient formulation and product development.

Symetis

Series B in 2009
Symetis is a Swiss company based in Ecublens that specializes in developing innovative minimally invasive heart valve replacement therapies. The company focuses on improving patient care and safety through its proprietary Acurate™ Aortic Valve Replacement System, which features a unique self-positioning design. This design allows for easier implant positioning and alignment, enhancing the overall user experience for healthcare providers. Symetis aims to address the needs of patients suffering from aortic valve stenosis, enabling the effective treatment of severe cardiac valve conditions through its advanced transcatheter aortic valve implantation devices.

Omnisens

Venture Round in 2008
Omnisens SA, founded in 1999 as a spin-off from the Swiss Federal Institute of Technology, specializes in optic-based real-time asset integrity monitoring solutions for the energy industry. The company develops advanced fiber optic sensing technologies that enable continuous monitoring of critical infrastructures, including pipelines, subsea umbilicals, and power transmission lines. These solutions facilitate early detection of leaks, geohazards, and other threats to asset integrity, ensuring optimal performance and safety. Omnisens offers a range of monitoring techniques, such as Distributed Temperature and Strain Sensing and Distributed Acoustic/Vibration Sensing, which measure subtle changes in temperature, strain, and vibration. The company's services extend to application engineering, commissioning, and maintenance, and it operates globally through system integrators and resellers. With a focus on the oil and gas, power, and civil engineering sectors, Omnisens is recognized as a leader in providing reliable monitoring solutions that enhance operational efficiency and reduce risks. The company is headquartered in Morges, Switzerland, with an additional office in Rio de Janeiro, Brazil.

SENSIMED

Series A in 2007
Sensimed AG is a medical devices company based in Lausanne, Switzerland, founded in 2003. The company specializes in the design, development, and commercialization of integrated micro-systems for medical applications, particularly focusing on glaucoma management. Its flagship product, the SENSIMED Triggerfish, is a soft, single-use contact lens that enables continuous monitoring of intraocular pressure (IOP) fluctuations in glaucoma patients over a 24-hour period. The Triggerfish system includes disposable sensors, an adhesive antenna for communication, a battery-powered recorder for data collection, and software for data management and analysis. Sensimed aims to enhance personalized treatment for glaucoma patients by analyzing the collected data to identify pathological patterns and improve clinical outcomes. The company's products are distributed through partners across Europe, Asia-Pacific, the Middle East, and the Americas. As of December 2019, Sensimed operates as a subsidiary of SEED Co., Ltd.

Datamars

Venture Round in 2006
Datamars is a company that specializes in high-performance radio frequency identification (RFID) solutions, primarily focusing on the animal, livestock, and textile identification markets. It provides a range of services and infrastructure aimed at livestock management, including tissue sampling ear tags, readers for animal identification, and devices such as plate meters and drafters to monitor the health performance of livestock. Additionally, Datamars plays a significant role in helping pet owners reunite with their lost animals, enhancing the overall connection between pets and their owners. Through its innovative technology, the company aims to improve efficiency and reliability in animal identification and management.

Kuros Biosciences

Post in 2005
Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.

Kuros Biosciences

Post in 2005
Kuros Biosciences AG is a biopharmaceutical company based in Schlieren, Switzerland, dedicated to the discovery, development, and commercialization of innovative products for tissue repair and regeneration. Founded in 2000 as a spin-off from the Eidgenössische Technische Hochschule Zürich, Kuros has developed a robust pipeline of biopharmaceuticals targeting chronic diseases. Its key products include Neuroseal, a novel biomaterial for dural sealing, and the MagnetOs family of bone graft substitutes used in orthopedic, spinal, and dental applications. MagnetOs is approved for use in the EU and the US, with further formulations under development for regulatory submission. Kuros also has a range of clinical-stage products, including KUR-111 and KUR-113, which have completed Phase II clinical trials for treating specific bone fractures. The company has engaged in significant clinical research, enrolling over 600 patients in multinational trials, generating promising data regarding safety and efficacy in various applications, particularly within orthobiologics.

Addex Therapeutics

Series B in 2004
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company based in Geneva, Switzerland, that specializes in the discovery, development, and commercialization of small-molecule drugs targeting central nervous system (CNS) disorders. The company primarily focuses on allosteric modulators, a novel class of orally available drugs that interact with G-protein coupled receptors, potentially offering advantages over traditional therapeutic approaches. Its lead product candidates include Dipraglurant for treating Parkinson's disease-related dyskinesia and dystonia, ADX71149 for epilepsy and other CNS disorders, and GABAB PAM for addiction. Addex has established a collaboration with Janssen Pharmaceuticals Inc. to develop mGluR2PAM compounds aimed at addressing various health issues. Founded in 2002, Addex Therapeutics continues to advance its innovative drug discovery platform to improve therapeutic outcomes for patients with neurological conditions.

immatics biotechnologies

Series A in 2004
immatics is a biopharmaceutical company focused on the discovery of true targets for cancer immunotherapies with the development of the right T cell receptors. The company's customized Adoptive Cell Therapies (ACTengine) and antibody-like TCR Bispecifics are the two main product classes in the pipeline (TCER). With a focus on particularly difficult-to-treat solid malignancies, each therapy modality has unique characteristics to create the desired therapeutic impact for patients at various disease stages and with various types of tumors. immatics biotechnologies was established in 2000 by Hans Rammensee, Harpreet Singh, and Steffen Walter in Tübingen, Baden-Wurttemberg.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.